medigraphic.com
ISSN 2594-1526 (Electronic)
Antes Revista del Instituto Nacional de Enfermedades Respiratorias

 Ver anteriores al 2010

2007, Number 2

<< Back Next >>

Neumol Cir Torax 2007; 66 (2)

Cost-effectiveness of tiotropium bromide in the chronic obstructive pulmonary disease

Idrovo-Velandia AJ, Vega-Hernández G, Rivas-Bocanegra RE, Zapata-Sánchez L

Language: Spanish
References: 17
Page: 75-80
PDF size: 89.23 Kb.


ABSTRACT

Introduction: In the last decades chronic obstructive pulmonary disease (COPD) has an increasing occurrence in Mexico, making it an important area of expenditure for the health sector. As control of exacerbations are a keystone from the clinical and economic point of view, it’s important to evaluate the anticholinergics to define which is the most cost-effective.
Material and methods: A Markov model was developed with a time horizon of 1 year. The main health outcome measure was the number of exacerbations prevented for both tiotropium and ipratropium which was 65 and 54% respectively, based on a clinical trial. Cost were estimated using institutional (IMSS) prices and considering: diagnosis, ambulatory treatment and mild, moderate or severe exacerbation’s treatment.
Results: Tiotropium is a dominant therapy for the treatment of COPD having a higher effectiveness and lower average costs incurred. Incremental cost-effectiveness ratio shows a saving $7,180 mxp with tiotropium.
Conclusions: Tiotropium clearly shows clinical and economic benefit reducing costs of treatment for patients with COPD and improving health outcomes.


REFERENCES

  1. Sansores RH, Ramírez-Venegas A. Segundo Consenso Mexicano para el diagnóstico y tratamiento de la EPOC. Rev Inst Nal Enf Resp Mex 2003; 16(Supl): 7-50.

  2. Menezes AM, Pérez-Padilla R, Jardín JR, et al. Chronic obstructive pulmonary disease in five Latin American cities (The PLATINO study): a prevalence study. Lancet 2005; 366: 1875-1881.

  3. Grupo de Trabajo de la Asociación Latinoamericana del Tórax (ALAT). Actualización de las recomendaciones ALAT sobre la exacerbación infecciosa de la EPOC. Arch Bronconeumol 2004; 40: 315-325.

  4. Tovar-Guzmán VJ, López-Antuñano FJ, Rodríguez-Salgado N. Recent trends in mortality due to chronic obstructive pulmonary disease (COPD) in Mexico, 1980-2002. Arch Med Res 2005; 36: 65-69.

  5. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making 1983; 3: 419-458.

  6. Weinstein MC. Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics 2006; 24: 1043-1053.

  7. García-Ruiz AJ, Leiva-Fernández F, Martos-Crespo F. Análisis del coste-eficacia del tiotropio frente al ipratropio y salmeterol. Arch Bronconeumol 2005; 41: 242-248.

  8. Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 year’s treatment with tiotropium. Eur Respir J 2002; 19: 209-216.

  9. Barr RG, Bourbeau J, Camargo CA, Ram FS. Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis. Thorax 2006; 61: 854-862.

  10. Instituto Mexicano del Seguro Social (IMSS) compró bienes terapéuticos. Disponible en: http://200.34.143.57:8080/wijsp/PDF_IMSS/IMSSComproBienesTerapeuticos.pdf Consultado el 17 de enero de 2006.

  11. Secretaría General del IMSS. Costos unitarios para la determinación de créditos fiscales derivados de capitales constitutivos, inscripciones improcedentes y atención a no derechohabientes. Diario Oficial de la Federación, 9 de marzo de 2004.

  12. Consejo Nacional de Población. México en cifras. Proyecciones de Población 2000-2050. Disponible en URL: www.inegi.com. Consultado el 20 enero 2006.

  13. Instituto Mexicano del Seguro Social. Información estadística en salud. Población adscrita a médico familiar. Total nacional 2004. Disponible en URL: http://www.imss.gob.mx/dpm/dties/Celula.aspx? ID=SC01_01_00_01_02&OPC=opc02&SRV=SRV02&Men=1

  14. Oostenbrink JB, Rutten-van Molken MP, Al MJ, Van Noord JA, Vincken W. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J 2004; 23: 241-249.

  15. Oostenbrink JB, Rutten-van Molken MP, Monz BU, FitzGerald JM. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health 2005; 8: 32-46.

  16. Schramm W. Economic value of tiotropium in the treatment of chronic obstructive pulmonary disease. Schweiz Rundsch Med Prax 2005; 94: 1803-1810.

  17. Navarro-Reynoso F. Efecto de las combinaciones salbutamol-ipratropio y salbutamol-tiotropio inhalados y teofilina vía oral en pacientes con EPOC. Análisis de costo/efectividad. Rev Inst Nal Enf Resp Mex 2006; 19: 122-126.




2020     |     www.medigraphic.com